03:12 PM EDT, 05/08/2024 (MT Newswires) -- Aldeyra Therapeutics ( ALDX ) said Wednesday the first patient has been enrolled in a phase 3 dry eye chamber trial of reproxalap in dry eye disease.

Reproxalap is an investigational reactive aldehyde species modulator, and the trial is designed to support the resubmission of a new drug application, the company said.

The trial will assess ocular discomfort in patients with dry eye disease, the company said.

Aldeyra expects to resubmit a new drug application for reproxalap to the US Food and Drug Administration for the treatment of dry eye disease in H2.

The company's shares fell 3% in recent trading Wednesday.

Price: 4.05, Change: -0.13, Percent Change: -3.00